Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Phio Pharmaceuticals Corp. (PHIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.01, with a market capitalisation of $11.97M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.81 to $4.19. This page covers its latest market performance, valuation, price trends and company information.
$11.97M | |
$1.00 | |
$3,118.50 | |
$0.81 | |
$1.02 | |
-- | |
618.36K | |
-- | |
$4.19 | |
$0.81 | |
-- | |
-- |
Phio Pharmaceuticals Corp. (PHIO) is trading at $1.01 in pre-market trading as of 2026-09-16 08:01:00, down 1.47% ($0.02) from the previous close of $1.02
Pre-market trading shows how investors are pricing PHIO before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Phio Pharmaceuticals Corp. (PHIO) moved from $1.08 to $1.01, representing a decline of 6.94% ($0.08).
The stock traded between $0.98 and $1.13 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 131.11 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.7%
PHIO is currently trading at $1.01, placing it 5.7% of the way from its 52-week low of $0.81 to its 52-week high of $4.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Phio Pharmaceuticals Corp. (PHIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.